Loading clinical trials...
Loading clinical trials...
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Conditions
Interventions
Phase 1b: APG-115+pembrolizumab
Locations
21
United States
University of Arizona Cancer Center
Tucson, Arizona, United States
Highlands Oncology
Rogers, Arkansas, United States
UCLA Hematology & Oncology Clinic
Los Angeles, California, United States
Sarcoma Oncology Research Center
Santa Monica, California, United States
Children's National Research Institute
Washington D.C., District of Columbia, United States
Sarah Cannon/FCSRI
Fort Myers, Florida, United States
Start Date
August 29, 2018
Primary Completion Date
December 30, 2025
Completion Date
December 30, 2025
Last Updated
August 7, 2025
NCT02621021
NCT07177937
NCT03050268
NCT05969860
NCT03340506
NCT04693377
Lead Sponsor
Ascentage Pharma Group Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions